StockNews.AI
GELS
StockNews.AI
33 days

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

1. Gelteq partners with IDT Australia for a dedicated manufacturing facility. 2. IDT brings over 50 years of pharmaceutical expertise to support Gelteq. 3. The agreement aims to enhance gel-based product development and scaling. 4. IDT focuses on regulatory compliance for nutraceuticals and pharmaceuticals. 5. Gelteq targets global markets in pharmaceuticals, nutraceuticals, and pet care.

7m saved
Insight
Article

FAQ

Why Bullish?

The partnership with IDT is strategic and may enhance product speed to market. Historical partnerships in pharmaceutical sectors often lead to stock price increases due to expected growth.

How important is it?

The article discusses a significant partnership that could propel GELS's growth and market reach. Manufacturing capabilities directly affect product availability and revenue potential, impacting stock performance.

Why Long Term?

The establishment of the facility will take time to realize benefits, but strong partnerships lead to sustained growth as seen in other pharmaceutical companies.

Related Companies

IDTPFEJNJ
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets. IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs). “Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.” Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.” Highlights of the Agreement: Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth. About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com and our SportsGel brand website www.sportsgel.com. Gelteq Contact: Investor RelationsMatt Kreps, Darrow Associates IR+1-214-597-8200mkreps@darrowir.com Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

Related News